Wells Fargo lowered the firm’s price target on Icon (ICLR) to $220 from $245 and keeps an Equal Weight rating on the shares ahead of quarterly results. The firm has a neutral relative view of the acquisition of PRA Health Sciences (PRAH) as well as continued pharma/biotech industry trends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICLR: